Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion type Assertion NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_head.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_provenance.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion evidence source_evidence_literature NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_provenance.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion SIO_000772 24568968 NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_provenance.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion wasDerivedFrom befree-2016 NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_provenance.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion wasGeneratedBy ECO_0000203 NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_provenance.